Sidoti Predicts Reduced Earnings for Phio Pharmaceuticals

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) – Research analysts at Sidoti reduced their Q2 2026 earnings per share (EPS) estimates for Phio Pharmaceuticals in a report released on Monday, May 11th. Sidoti analyst A. Hantman now forecasts that the company will post earnings per share of ($0.37) for the quarter, down from their prior estimate of ($0.24). The consensus estimate for Phio Pharmaceuticals’ current full-year earnings is ($1.21) per share. Sidoti also issued estimates for Phio Pharmaceuticals’ Q3 2026 earnings at ($0.31) EPS, Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($1.35) EPS, Q1 2027 earnings at ($0.20) EPS, Q2 2027 earnings at ($0.22) EPS, Q3 2027 earnings at ($0.24) EPS, Q4 2027 earnings at ($0.25) EPS and FY2027 earnings at ($0.91) EPS.

Phio Pharmaceuticals (NASDAQ:PHIO) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10).

Several other research firms have also issued reports on PHIO. HC Wainwright restated a “buy” rating and set a $14.00 price target on shares of Phio Pharmaceuticals in a research report on Tuesday, February 10th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $14.00.

Phio Pharmaceuticals Stock Performance

Shares of Phio Pharmaceuticals stock opened at $1.10 on Wednesday. Phio Pharmaceuticals has a 52-week low of $0.81 and a 52-week high of $4.19. The company has a fifty day moving average of $1.21 and a 200-day moving average of $1.24. The stock has a market capitalization of $12.78 million, a price-to-earnings ratio of -0.80 and a beta of 0.84.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Phio Pharmaceuticals stock. Geode Capital Management LLC increased its position in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) by 60.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 92,638 shares of the company’s stock after purchasing an additional 34,732 shares during the quarter. Geode Capital Management LLC owned approximately 0.86% of Phio Pharmaceuticals worth $97,000 as of its most recent filing with the Securities & Exchange Commission. 57.31% of the stock is currently owned by institutional investors and hedge funds.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals, Inc (NASDAQ: PHIO) is a clinical‐stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next‐generation RNAi compounds with potential applications in oncology and immuno‐oncology.

Phio’s TRiMTM platform is designed around the delivery of synthetic, double‐stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion.